Cartesian Therapeutics宣布Descartes-08针对SLE患者的二期试验显示强效信号,并扩展临床开发至肌炎

投资观察
Nov 20, 2025

11月13日 - Cartesian Therapeutics Inc:*Cartesian Therapeutics宣布Descartes-08针对SLE患者的二期试验显示强效信号,并扩展临床开发至肌炎*Cartesian - 在二期开放标签试验中,SLE患者使用Descartes-08后观察到100%的LLDAS反应率,且在第3个月的跟进中得以确认*Cartesian Therapeutics Inc - Cartesian计划暂停进一步的Descartes-08在SLE中的开发*Cartesian Therapeutics Inc - 计划暂停Descartes-15的开发,以优先考虑Descartes-08在重症肌无力(MG)和肌炎中的机会*Cartesian:肌炎无缝适应性临床试验设计提供了单一关键试验的潜在机会,预计在2026年上半年开始 ((投资者简报; email: reutersinvestor.briefs@thomsonreuters.com)) 源日期/时间 = 13-11-2025 21:05:04.977 GMT

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10